Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
immune checkpoint inhibitor
immunotherapy
local therapy
non-small cell lung cancer
oligoprogression
resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Mar 2021
15 Mar 2021
Historique:
received:
06
02
2021
revised:
09
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients' selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to personalize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review's aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).
Identifiants
pubmed: 33803958
pii: cancers13061300
doi: 10.3390/cancers13061300
pmc: PMC7999258
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Int J Cancer. 2015 Apr 15;136(8):1967-75
pubmed: 25242168
Future Oncol. 2019 Sep 1;15(25):2915-2931
pubmed: 30793926
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
Future Oncol. 2020 Aug;16(23):1707-1713
pubmed: 32687405
Clin Cancer Res. 2016 Feb 1;22(3):680-90
pubmed: 26832745
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340408
J Clin Oncol. 2020 May 10;38(14):1580-1590
pubmed: 32078391
J Cancer Res Ther. 2020 Jul-Sep;16(4):941-945
pubmed: 32930148
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
Ann Oncol. 2014 Nov;25(11):2277-2284
pubmed: 25210016
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Cancer Lett. 2018 Dec 1;438:17-23
pubmed: 30217563
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Crit Rev Oncol Hematol. 2020 Apr;148:102894
pubmed: 32062314
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385724
Cancer Immunol Res. 2015 Jun;3(6):602-9
pubmed: 25795007
Nat Commun. 2020 Jan 31;11(1):661
pubmed: 32005826
Case Rep Oncol. 2019 Nov 21;12(3):866-871
pubmed: 31824281
Nat Rev Immunol. 2006 Jun;6(6):433-46
pubmed: 16724098
Cancer J. 2020 Mar/Apr;26(2):129-136
pubmed: 32205537
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Cancer Treat Rev. 2019 Nov;80:101892
pubmed: 31522079
Future Oncol. 2019 Aug;15(23):2699-2706
pubmed: 31282758
Clin Cancer Res. 2019 Aug 15;25(16):4881-4887
pubmed: 30910855
J Thorac Oncol. 2018 Jun;13(6):831-839
pubmed: 29578107
Nature. 2016 Nov 17;539(7629):443-447
pubmed: 27828943
World J Clin Oncol. 2019 Oct 24;10(10):318-339
pubmed: 31799148
Front Immunol. 2015 Oct 07;6:516
pubmed: 26500653
J Thorac Oncol. 2017 Feb;12(2):194-207
pubmed: 27729297
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Curr Oncol. 2019 Feb;26(1):e81-e93
pubmed: 30853813
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Lung Cancer. 2019 Dec;138:109-115
pubmed: 31683093
Lancet Respir Med. 2019 Oct;7(10):835-837
pubmed: 31401050
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Rev Clin Oncol. 2016 Jun;13(6):370-83
pubmed: 27000958
Eur J Cancer. 2020 May;131:27-36
pubmed: 32276179
Cancer Sci. 2018 Dec;109(12):3993-4002
pubmed: 30447042
Int J Cancer. 2018 Jun 1;142(11):2344-2354
pubmed: 29318609
Cancer Discov. 2017 Jul;7(7):675-693
pubmed: 28630051
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
J Thorac Oncol. 2017 Feb;12(2):179-193
pubmed: 27780780
Oncogene. 2002 Aug 12;21(35):5496-503
pubmed: 12154410
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Transl Cancer Res. 2019 Dec;8(Suppl 6):S612-S617
pubmed: 35117143
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Sci Transl Med. 2010 Oct 27;2(55):55ra78
pubmed: 20980695
Clin Transl Oncol. 2020 May;22(5):759-771
pubmed: 31368078
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Eur J Cancer. 2017 Nov;86:296-304
pubmed: 29059635
J Transl Med. 2014 Nov 13;12:294
pubmed: 25388653
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Lung Cancer. 2013 Sep;81(3):337-342
pubmed: 23891507
Lung Cancer. 2020 Feb;140:99-106
pubmed: 31911324
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Nat Rev Drug Discov. 2018 Jul;17(7):509-527
pubmed: 29904196
Thorac Cancer. 2020 Aug;11(8):2357-2360
pubmed: 32567218
Ther Adv Med Oncol. 2019 Aug 28;11:1758835919870360
pubmed: 31497071
BMC Cancer. 2007 Jan 03;7:2
pubmed: 17201906
Curr Top Microbiol Immunol. 2017;410:127-156
pubmed: 28900677
Cancer. 2019 Apr 15;125(8):1341-1349
pubmed: 30768786
J Thorac Dis. 2019 Dec;11(12):4972-4981
pubmed: 32030213
Clin Cancer Res. 2014 Dec 15;20(24):6593-604
pubmed: 25294904
J Thorac Oncol. 2018 Jan;13(1):106-111
pubmed: 29101058
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Am J Transl Res. 2011 Feb;3(2):166-79
pubmed: 21416059
Adv Immunol. 2000;74:181-273
pubmed: 10605607
Lung Cancer. 2018 Jun;120:62-69
pubmed: 29748017
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Nat Rev Clin Oncol. 2013 Oct;10(10):571-87
pubmed: 23999218
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1023-8
pubmed: 23277554
Lung Cancer. 2020 Apr;142:106-113
pubmed: 32126451
Cancer Discov. 2020 Aug;10(8):1158-1173
pubmed: 32439653
Eur Respir Rev. 2015 Dec;24(138):582-93
pubmed: 26621972
Recent Results Cancer Res. 2018;211:67-75
pubmed: 30069760
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Lung Cancer. 2013 Sep;81(3):440-444
pubmed: 23810573
J Clin Oncol. 2012 Dec 20;30(36):4501-7
pubmed: 23109689
Expert Rev Anticancer Ther. 2020 Mar;20(3):221-228
pubmed: 32141356
Curr Treat Options Oncol. 2020 Jul 27;21(8):69
pubmed: 32720019
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
BMC Cancer. 2020 Jun 15;20(1):557
pubmed: 32539805
J Clin Invest. 1991 Jan;87(1):284-92
pubmed: 1898655
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
J Transl Med. 2011 Nov 28;9:204
pubmed: 22123319
Curr Oncol Rep. 2020 Apr 16;22(5):41
pubmed: 32296957
Cancer Commun (Lond). 2020 Dec;40(12):649-654
pubmed: 33169937
Lung Cancer. 2017 Oct;112:90-95
pubmed: 29191606
ESMO Open. 2020 Jan;5(1):
pubmed: 32516116
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301
J Immunol. 2008 Dec 1;181(11):7617-29
pubmed: 19017950